Article Text

Download PDFPDF
Acute coronary syndromes
New anticoagulant agents in acute coronary syndromes
  1. Thomas Höchtl1,
  2. Serdar Farhan1,
  3. Johann Wojta2,
  4. Kurt Huber1
  1. 13rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
  2. 2Deptartment of Cardiology, Medical University, Vienna, Austria
  1. Correspondence to Dr Kurt Huber, 3rd Department of Internal Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Montleartstrasse 37, A-1160 Vienna, Austria; kurt.huber{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In the development of new antithrombotic drugs the main target has become the improvement of the net clinical benefit (reduction of major bleeding complications as well as reduction of thromboembolic ischaemic complications), rather than a higher efficacy in terms of reduction of thromboembolic ischaemic events only.1 Standard antithrombin treatment of non-ST elevation acute coronary syndromes (NSTE-ACS) in recent years has consisted of unfractionated heparin (UFH) or low molecular weight heparin (LMWH), especially enoxaparin, which has been tested most extensively within this group of agents.w1 w2 In patients with ST elevation myocardial infarction (STEMI) the use of UFH is still the major antithrombotic regimen when primary percutaneous coronary intervention (PCI) is performed. As an adjunct antithrombin to thrombolytic therapy, enoxaparin has been proven to be more efficacious than UFH, with comparable bleeding rates, and is widely used.w3

In the past few years, new antithrombins have been investigated in patients with acute coronary syndromes (ACS). Based on favourable data obtained from large prospective randomised clinical trials, the indirect anti-Xa inhibitor fondaparinux, as well as the direct thrombin inhibitor bivalirudin, have made it into the updated guidelines of the American College of Cardiology/American Heart Association (ACC/AHA) and the European Society of Cardiology (ESC) (tables 1 and 2).1–5 Moreover, new direct anti-Xa inhibitors such as apixaban, rivaroxaban, and otamixaban, as well as the direct antithrombin dabigatran, are still under clinical investigation, and the results of phase II dose finding and safety studies have been published recently.

View this table:
Table 1

Comparison between European and American guidelines for the antithrombotic management of patients with non-ST elevation acute coronary syndromes

View this table:
Table 2

American guidelines for antithrombotic management in patients with ST elevation myocardial infarction

Figure 1 shows the onset of action of the different antithrombins in the coagulation cascade. This article provides an overview of the results …

View Full Text


  • Competing interests In compliance with EBAC/EACCME guidelines, all authors participating in Education in Heart have disclosed potential conflicts of interest that might cause a bias in the article. The authors have no competing interests.

  • Provenance and peer review Commissioned; internally peer reviewed.